Allogeneic T Cell Therapies Patent Landscape Report 2026 Edition

The global allogeneic T cell therapies market is expected to grow at a CAGR of 9.75% during the forecast period of 2026-2035. The rising demand for cutting-edge immunotherapies to treat cancer and other immune-related disorders is boosting patent applications for these therapies. Patents are focused on advanced technologies such as gene editing, TCR-T cell therapy, off-the-shelf t cells, immune evasion and modulation, among others.

Patent Landscape Report Coverage

The Global Allogeneic T Cell Therapies Patent Landscape Report provides a comprehensive and in-depth analysis of the patents in this growing industry. The key sections captured in the report for allogeneic T-cell therapies include a thorough examination of the patent portfolios of key players, covering aspects such as the number of patents and types of technologies patented. It includes the latest trends, geographical distribution of patents, top IP player profiles, technological segmentation, and patent valuation associated with allogeneic T-cell therapies. The breakdown of patents by technical segments is provided, giving more clarity on the specific areas of innovation within allogeneic T-cell therapy technologies.

Key Inclusions:

• Patent Valuation Analysis

An evaluation and competitive benchmarking of key members of unique patent families are covered in the analysis for allogeneic T cell therapies technologies. The important parameters have been taken into consideration including IP document, year of application, number of citations, time to expiry, and jurisdiction associated with allogeneic T cell therapies.

• Analysis of Patent Applications

A comprehensive summary of several patent applications which were filed across different jurisdictions for allogeneic T-cell therapies and their relative value are covered. The analysis will cover the capital in terms of innovation and innovation type.

• Analysis of Granted Patents

Detailed analysis of the granted patents across different jurisdictions for allogeneic T cell therapies and their relative value in the IP are covered in the final report.

What are Allogeneic T Cell Therapies?

Allogeneic T-cell therapies treat diseases like cancer and autoimmune disorders by using T cells from a healthy donor. The recipient's body contains aberrant cells, which the donor's T cells are specifically designed to target and eliminate. Allogeneic T-cell therapies offer ready-made solutions that can be used for multiple patients, improving accessibility and scalability in contrast to autologous therapies, which depend on a patient's own cells.

The components of allogeneic T-cell therapies include chimeric antigen receptor (CAR) T-cell therapies, T-cell receptor (TCR) therapies, and others. Chimeric antigen receptor (CAR) T cell therapy, a novel type of immunotherapy, involves genetically modifying a patient's T cells to produce a receptor that specifically targets cancer cells. These T cells are reintroduced into the patient after being modified to detect and eliminate cancer cells that express the specific antigen. Blood cancers like leukemia and lymphoma have shown great promise in response to CAR-T therapies, offering a promising therapeutic alternative.

Allogeneic T-Cell Therapies Industry Growth Drivers

Technological Advancements in Gene Editing is Expected to Boost the Patent Industry Growth

The development of allogeneic T-cell therapies is being revolutionized by developments in gene-editing technologies, such as CRISPR-Cas9. For instance, CRISPR Therapeutics and Vertex Pharmaceuticals received a patent in 2020 for using CRISPR in gene-edited allogeneic T-cell therapies, which could increase the efficacy and scalability of these treatments.

There is an increase in patent activity which focuses on enhancing the performance of allogeneic T cell therapies. In 2023, 1,628 patents were granted which increased to 1,740 by 2024. Patents covering these technologies are crucial for companies and thus impact the allogeneic T-cell therapies patent landscape.

Rising Cancer Incidence is Expected to Propel Allogeneic T Cell Therapies Patent Industry

One of the main factors propelling the market for allogeneic T-cell therapies is the rising incidence of cancer worldwide. Allogeneic T-cell therapies are seen as a promising way to address different cancer types and improve patient outcomes as the need for more potent treatment options grows.

Allogeneic T-Cell Therapies Patent Segmentation

The report will cover the following sections in detail:

Analysis by Product Type

• Chimeric Antigen Receptor (CAR) T Cell Therapies
• T Cell Receptor (TCR) Therapies
• Others

Analysis by Indication

• Cancer
• Autoimmune Diseases
• Infectious Diseases
• Others

Allogeneic T-Cell Therapies Patent Segmentation Analysis

The breakup based on indication includes cancer, autoimmune diseases, infectious diseases, and others. To help control the immune response and reestablish equilibrium, allogeneic T cell therapies involve modifying and injecting T cells from a healthy donor into the patient. Targeting immune pathways is intended to lower inflammation and stop additional tissue damage. This method shows promise in the treatment of autoimmune diseases like multiple sclerosis, rheumatoid arthritis, and type 1 diabetes.

Allogeneic T-Cell Therapies Patent Jurisdiction Analysis

The United States is one of the leading jurisdictions for allogeneic T cell therapy patents, having around 49,000+ patents. The presence of big companies, well-established healthcare infrastructure, and advanced research and development activities contributes to the regional patent landscape significantly.

Patent Profile of Key Companies

Among the players with allogeneic T cell therapies patent families, new entrants have been identified, which can be either established companies or startups developing their first technology in the allogeneic T cell therapies field. Some of the major companies mentioned in this report (a non-exhaustive list) are as follows:

Immunovative Therapies Ltd

Based in Tel Aviv, Israel, this biotechnology company specializes in developing innovative allogeneic T-cell treatments for diseases of the immune system and cancer. With an emphasis on using T cells to develop more potent and patient-accessible therapies, the company is dedicated to developing next-generation immunotherapy treatments. Immunovative wants to revolutionize cancer treatment through its cutting-edge research.

Novartis AG

It is a leading healthcare organization with headquarters in Basel, Switzerland, that specializes in cutting-edge therapies like allogeneic T cell therapies. By developing cutting-edge cell therapies like CAR-T to treat a variety of cancers, the company is at the forefront of immuno-oncology. Novartis is committed to developing novel treatments and applying its knowledge of biotechnology to improve the lives of people with difficult medical conditions.

Other companies include Mirror Biologics Inc., Gilead Sciences Inc., and Immatics Biotechnologies Gmbh, among others.

Reasons to Purchase this Report

The allogeneic T cell therapies patent report provides information on the intellectual property (IP) position and strategy of key players. This report can help companies and players looking to enter or invest in this field by:

• Competitive Advantage: The landscape reveals the market leaders, potential partners and innovators and makes it understandable which companies have important patents in this field of allogeneic T cell therapies.
• Innovation Insights: The patent analysis reveals new innovations and technologies in allogeneic T cell therapies.
• Market Positioning: Companies with strong patent portfolios gain a competitive advantage because their intellectual property assets differentiate their products. Understanding their intellectual property strategy reveals the market position of new entrants and potential barriers to entry within the allogeneic T cell therapies patent landscape.
• Risk Assessment: In technology-intensive fields such as allogeneic T-cell therapies, risks of IP infringement are common. Analyzing patent landscapes helps companies assess risk, develop mitigation strategies, and inform licensing, partnering, and acquisition decisions.

Key Questions Answered in the Allogeneic T Cell Therapies Patent Landscape Report

• Who are the key players in the allogeneic T cell therapies patent landscape?
• How is the patent portfolio distributed geographically?
• What are the emerging trends in allogeneic T-cell therapy patents?
• How has the patent landscape evolved over time?
• What are the strategic insights for market players and investors?
• What is the technological focus of patents in the allogeneic T-cell therapies industry?
• How do patent strategies impact competitive advantage?
• What are the implications of patent filings in allogeneic T-cell therapies?
• What are the challenges and opportunities in the allogeneic T cell therapies patent landscape?
• What are the regulatory and legal considerations?
• What technological innovations have recently emerged in allogeneic T-cell therapies?